Tangled in the web of mass generic consolidation? Let Scrip explain
This article was originally published in Scrip
Executive Summary
The drive for consolidation in the generic pharma sector is generating plenty of headlines and hot air. For those feeling a little confused about what exactly is going on with those generic company M&A pursuits, here's a brief summary of the latest.
You may also be interested in...
Perrigo's Papa: Bridge Over Valeant's Troubled Waters Or Shark Bait?
Valeant Pharmaceuticals International Inc. hired Perrigo Co. PLC's Chairman and Chief Executive Joseph Papa to replace CEO Michael Pearson, but will Papa bridge the gaps between Valeant and its shareholders, debtors and the politicians who are demanding information about the company's drug pricing policies? Or, like Pearson, will he be bitten by the sharks in Valeant's troubled waters?
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.